The antibody cocktail AZN. Se has allowed the use of AstraZeneca Plc’s L for COVID-19 prevention in a medical tourism in southern China’s Hainan province ahead of national approval, local media reported on Tuesday.
China is allowing the early use of new medical products in the Qionghai City Special Zone under several preferential policies granted to the region to advertise medical products to domestic and foreign visitors.
Hainan Daily, subsidized through the Communist Party’s provincial authority, reported that a shipment of 21. 98 million yuan ($3. 28 million) of AstraZeneca Evusheld’s antibody-based treatment ended local customs formalities as special imports.
The drug has been legal in many regions, including the United States, the United Kingdom, and the European Union, to prevent infections in other people whose immune systems are too weak to respond to vaccines.
“We expect Evusheld to be available in more countries as soon as possible,” an AstraZeneca spokesman said, without offering the main points of any other plans for the drug in China.
Other Western products that have not yet been legal for domestic use and are lately available at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan come with the breast cancer drug NOVN. S from Novartis Piqray and the drug for fungal infections GILD. Or Gilead AmBisome.
Mrk cancer treatment. Merck’s N, Keytruda, also authorized import to the domain in 2016 before receiving local approval two years later.